592 results on '"Greillier, Laurent"'
Search Results
152. The clinical utility of tumor mutational burden in non-small cell lung cancer
153. Additional file 1: of PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trial
154. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06)
155. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
156. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06).
157. Enrolling patients in clinical trials: Advice from close family and friends.
158. Profile of cancer-screening resistant individuals (EDIFICE 6).
159. Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).
160. Characteristics of individuals self-reporting a higher-than-average risk of cancer.
161. Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.
162. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
163. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
164. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
165. Personalised medicine for nonsmall cell lung cancer
166. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
167. Bevacizumab Plus Radiosurgery for Nonsquamous Non–Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?
168. Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial
169. Second-line treatments of small-cell lung cancers
170. Factors influencing colorectal cancer screening participation rates in 2016
171. Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).
172. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
173. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
174. Dépistage du cancer en France : 10 ans d’analyse des comportements par les enquêtes EDIFICE
175. Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians.
176. P2.04-003 Chemotherapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
177. OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial
178. P1.01-010 Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians
179. P1.03-040 Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey
180. P1.01-017 The Dramatic Shift of Lung Cancer toward Young in Prisons
181. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
182. Erratum to “Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network” [Lung Cancer, 97 (July 2016), 99–104]
183. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study
184. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
185. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
186. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
187. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
188. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
189. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
190. Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.
191. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.
192. Current and Former Smokers: Who Wants To Be Screened?
193. Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients
194. Optimization of cfDNA routine use for NSCLC genomic alteration analysis
195. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
196. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
197. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes
198. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
199. New oncogenes drivers in lung cancer—new therapeutic targets
200. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.